Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma

BackgroundRadical/cytoreductive nephrectomy or nephron-sparing surgery may be thought to be not safe or unfeasible in some renal cell carcinoma (RCC) patients in which tumor is locally advanced or highly complicated. Neoadjuvant therapy may reduce the volume of the tumor, thus facilitates surgery. The aim the study is to evaluate the efficacy and safety of neoadjuvant combination of pazopanib or axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) cell immunotherapy in those patients.MethodsData from 16 RCC patients who received neoadjuvant pazopanib (Group P, n=9) or axitinib (Group A, n=7) plus PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. A total of 9 participants that were potential candidates for radical/cytoreductive nephrectomy (RN/CN) had locally advanced tumor and 5 participants with partial nephrectomy (PN) absolute indications had highly complicated tumors. The efficacy outcomes were based on volume changes of the primary tumor, lymph nodes, and tumor thrombus in 13 participants with complete computed tomography (CT) imaging. The treatment-related toxicities and surgical complications were also reported.ResultsWith a median of 2.1 months treatment, the overall volume of the tumors decreased by a median of 42.30% [interquartile range (IQR): 19.37–66.78%]. Specifically, the median reduction of tumor volume was 88.77 and 15.50 cm³ in group P and group A, respectively (P=0.014). However, participants in Group P were more likely to experience grade 3 or 4 treatment-related adverse events (AEs) than those in Group A (44.4% vs. 0). Finally, all participants were candidates for appropriate surgery after neoadjuvant therapy (as assessed by the surgeon), and 10 participants accepted surgery, including 5 PN, 4 RN/CN, and 1 lymph node dissection. A solitary participant had Clavien grade IV acute renal failure required dialysis and another had grade II lymphatic leakage.ConclusionsNeoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK cells immunotherapy was well-tolerated and could effectively reduce the volume of tumors in locally advanced or highly complicated RCC patients.     

百球清（Baycox）对柔嫩艾美尔球虫的作用以及对球虫免疫力影响的研究

进行四项试验观察Ｂａｙｃｏｘ对柔嫩艾美尔球虫的作用及其对球虫免疫力影响。Ｂａｙｃｏｘ均以推荐浓度（２５ｐｐｍＴｏｌｔｒａｚｕｒｉｌ）混入水中任鸡自由饮用。以２０００卵囊剂量感染并立即给药的鸡，在感染后６－２０ｄ粪便中始终没有发现卵囊，表明Ｂａｙｏｏｘ具有杀虫作用而不是抑虫作用。以８×１０￣４卵囊剂量感染鸡，在感染前１ｄ和感染后０、１、２、３、４、５ｄ分别开始给药，根据血便数量和盲肠病变判断，Ｂａｙｃｏｘ的作用峰期是在感染后０－２ｄ之间。感染后第４ｄ再给药已无治疗作用。停药１ｄ后，药物残效对感染仍显出一定的抗球虫作用，但是停药２ｄ后，这种作用即基本消失。采用攻毒的方法表明Ｂａｙｃｏｘ不影响抗球虫免疫力的形成。     

肉苁蓉炮制对微量元素含量及对动物体内DNA合成率的影响

对不同方法炮制的肉苁蓉进行了肝脾脱氧核糖核酸合成率以及金属微量元素的测定分析。结果表明,蒸制盐大芸对“阳虚”动物脱氧核糖核酸及微量元素锌、锰、铜、铁的含量均高于其他的传统炮制品。     

急诊冠状动脉内支架植入治疗急性心肌梗死——围术期死亡和近期预后的研究

为评价急性心肌梗死(AMI)患者急诊经皮冠状动脉腔内成形(PTCA)和冠状动脉内支架植入围术期死亡和近期预后的影响因素,通过对74例行急诊冠状动脉内支架植入的AMI,术后6个月内的临床随访和冠状动脉造影随访,进行多因素相关回归分析。结果表明,多支病变患者的糖尿病、高血压和高血脂的合并比例明显高于单支病变患者;总围术期内死亡率为5.4％,剔除合并心源性休克患者后,死亡率为1.4％;12例75岁以上的患者中,2例死于心源性休克,1例死于心脏破裂,5例心源性休克患者死亡3例;术中非致命性合并症的发生率在单支和多支病变组之间差异无显著性(P>0.05);多元回归分析表明血流动力学状态和患者的年龄是决定AMI患者围术期死亡的独立相关因素;多支病变患者术后6个月内心脏事件发生率明显高于单支病变组;术前和术后6个月内的患者左心室射血分数(LVEF)明显改善;而且单支和多支病变组之间术后6个月时的LVEF之间无显著性差异。     

茶多酚与亚硒酸钠联合对EBV抗原表达的抑制作用

用间接免疫荧光法测定Ｒａｊｉ细胞和Ｂ９５－８细胞ＥＢ病毒抗原的表达。结果显示无细胞毒浓度的茶多酚与亚硒酸钠联合对Ｒａｊｉ细胞ＥＢＶ－ＥＡ表达有显著的抑制作用,优于单纯茶多酚或亚硒酸钠的抑制作用。两药显示相互协同增效的作用 。抑制率与药物浓度相关;单纯茶多酚对Ｂ９５－８细胞ＥＢＶ－ＶＣＡ表达无抵制作用,但茶多酚能增强亚硒酸钠对Ｂ９５－８细胞ＥＢＶ－ＶＣＡ表达的抵制作用,抑制率随药物浓度的升高而升高。     

雷公藤多甙的抗炎和免疫抑制作用

目的探讨雷公藤多甙(T     

胆汁泡蛋白ELISA检测法的建立与初步临床应用

目的 建立胆汁泡蛋白快速检测法,筛选有效的胆石症防治手段。方法 获取３３．５ｋｄ胆汁泡蛋白,通过微量抗原免疫法获得高效价抗体,建立ＥＬＩＳＡ标准曲线;并应用ＥＬＩＳＡ法测定正常人、胆石症患者胆汁和血清中泡蛋白含量,同时观察不同溶石防药和利胆冲剂、胆酸钠等对泡蛋白的影响。结果 建立了ＥＬＩＳＡ标准曲线,其曲线方程为Ｙ＝０．０３５Ｘ（ｒ＝０．９９）;正常人胆汁和血清中３３．５ｋｄ泡蛋白含量都明显较胆固     

小柴胡汤分解剂抗柯萨奇B3病毒感染及其对心肌炎防治作用的研究

目的 :探讨小柴胡汤分解剂在体外及体内抗柯萨奇 B3病毒 (CVB3)及保护心肌细胞的作用。方法 :用小柴胡汤分解剂通过体外微量细胞培养 ,作用于被 CVB3直接损伤的细胞模型及经腹腔感染 CVB3m Balb/ c小鼠心肌炎模型 ,分析不同浓度分解剂的效应。结果 :在体外细胞上分解剂 A、B液自 1∶ 32稀释度对 vero细胞的毒性作用已丧失 ,至 1∶ 2 5 6稀释度时 ,仍能对抗 CVB3对细胞致病变作用。在体内分解剂 A、B液治疗组小鼠 35只 ,心肌炎发生率 37.14% ;而 2 0只对照组小鼠心肌炎发生率 5 9.1% ,两者有显著性差异 (χ2 =4.6 8,P <0 .0 5 ) ,在预防给药组更为明显 (P <0 .0 1)。结论 :小柴胡汤分解剂 A、B液在体内、体外均具有抗病毒及保护心肌的作用。